Changes Afoot for the Treatment of Psoriatic Arthritis with Marked Gains in Preference and ... : vimarsana.com

EXTON, PA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Since the first US FDA-approved tumor necrosis factor (TNF) inhibitor in 2002 for the treatment of psoriatic arthritis (PsA), TNF’s have upheld

Related Keywords

Germany , Maxine Yarnall , Eli Lilly Taltz , Novartis Cosentyx , Linkedin , Spherix Network , Twitter , Eli Lilly , Spherix Global Insight Realtime Dynamix , Psoriatic Arthritis , Realtime Dynamix , Time Dynamix , Global Insights , Spherix Global Insights , Spherix Global Insight , Region ,